• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Myomo Reports First Quarter 2025 Financial and Operating Results

    5/7/25 5:11:00 PM ET
    $MYO
    Industrial Specialties
    Health Care
    Get the next $MYO alert in real time by email

    Revenue of $9.8 million

    Record 700 patients added to the pipeline

    More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training

    Conference call being held today at 4:30pm Eastern time

    Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2025.

    Financial and operating highlights for the first quarter of 2025 include the following (all comparisons are with the first quarter of 2024 unless otherwise indicated):

    • Revenue was $9.8 million, up 162%;
    • Revenue units were 182, up 100%; 45% of revenue units were from first quarter authorizations and orders
    • Medicare Part B patients represented 59% of first quarter 2025 revenue;
    • Orders and insurance authorizations were received for 213 MyoPro units, up 18%;
    • Backlog, which represents insurance authorizations and orders received but not yet converted to revenue, was 249 units as of March 31, 2025, down 9%;
    • A record 700 new candidates were added to the patient pipeline, up 42%;
    • There were 1,482 MyoPro candidates in the patient pipeline as of March 31, 2025, up 33%;
    • Gross margin was 67.2%, up 600 basis points;
    • Cost per pipeline add was $2,300, up 31%; and
    • Initial training of more than 300 certified prosthetist orthotists ("CPO's") was completed as of March 31, 2025. MyoPro certification classes now underway.

    Management Commentary

    "Our first quarter financial results were in line with expectations, yet several operating metrics were affected by continued utilization management by Medicare Advantage plans which impacted authorizations and orders, as well as changes to social media algorithms that disrupted lead flow and increased our cost per pipeline add during the first six weeks of the quarter. I'm pleased to report that both lead flow and pipeline adds rebounded in March and April," said Paul R. Gudonis, Myomo's Chairman and Chief Executive Officer.

    Financial Results

     

    For the Three Months

    Ended March 31,

     

    Period-

    to-Period

    Change

     

     

    2025

     

    2024

     

    $

     

    %

     

    Product revenue

    $

    9,831,814

     

    $

    3,754,389

     

    $

    6,077,425

     

     

    162

    %

    Cost of revenue

     

    3,222,184

     

     

    1,455,345

     

     

    1,766,839

     

     

    121

    %

    Gross profit

    $

    6,609,630

     

    $

    2,299,044

     

    $

    4,310,586

     

     

    187

    %

    Gross margin %

     

    67.2

    %

     

    61.2

    %

     

     

     

    6.0

    %

    Revenue for the first quarter of 2025 was $9.8 million, up 162% compared with the first quarter of 2024, driven by an increase in the number of revenue units and by a higher average selling price ("ASP"). First quarter 2024 revenues included very few Medicare patients as CMS fees for the MyoPro became effective in April 2024. Myomo recognized revenue on 182 MyoPro units in the first quarter of 2025, up 100% over the same quarter a year ago. ASP was approximately $54,000 in the first quarter, up 31% over the same period a year ago. Revenue from patients with Medicare Part B represented 59% of first quarter 2025 revenue. First quarter revenue was the Company's highest velocity revenue, with 45% of revenue generated from authorizations and orders received during the quarter.

    Gross margin for the first quarter of 2025 was 67.2%, compared with 61.2% for the first quarter of 2024. The increase was driven primarily by a higher ASP and higher fixed overhead absorbed into inventory.

    Operating expenses for the first quarter of 2025 were $10.1 million, an increase of 64% compared with the first quarter of 2024. The increase was primarily due to higher payroll expense, reflecting higher headcount to support expected growth in the direct billing channel, increased engineering activity resulting in higher research and development spending and higher advertising expenditures. Advertising costs of $1.6 million were up 104% over the first quarter of 2024. Social media algorithm changes resulted in a cost per pipeline add of $2,300, an increase of 31% compared with the first quarter of 2024.

    Operating loss for the first quarter of 2025 was $3.5 million, compared with an operating loss of $3.9 million for the first quarter of 2024. Net loss for the first quarter of 2025 was $3.5 million, or $0.08 per share, compared with a net loss of $3.8 million, or $0.10 per share, for the first quarter of 2024.

    Adjusted EBITDA for the first quarter of 2025 was $(2.8) million, compared with Adjusted EBITDA of $(3.5) million for the first quarter of 2024. A reconciliation of GAAP net loss to this non-GAAP financial measure appears below.

    Operations Update

    The MyoPro patient pipeline was 1,482 patients as of March 31, 2025, compared with 1,112 patients as of March 31, 2024, an increase of 33%. Despite temporary lead generation challenges, a record 700 medically-qualified patients were added to the pipeline during the first quarter of 2025, an increase of 42% compared with the same period a year ago. The Company generated 213 MyoPro authorizations and orders in the first quarter of 2025, an increase of 18% compared with the same period a year ago. Higher velocity of revenue affected the ending backlog, which was 249 patients as of March 31, 2025, a decrease of 9% compared with March 31, 2024.

    Cash Position

    Cash, cash equivalents and short-term investments as of March 31, 2025 were $21.5 million. Cash decreased by approximately $3.3 million compared with December 31, 2024. Cash used in operating activities was $2.7 million for the first quarter of 2025, compared with $3.2 million used in the first quarter of 2024.

    Business Outlook

    "While second quarter revenue growth is expected to reflect temporary lead generation challenges experienced early in the first quarter, we continue to expect revenue growth to accelerate in the second half of 2025," added Mr. Gudonis. "We expect second quarter revenue to be in the range of $9.0 million to $9.5 million. For the full year, we continue to expect revenue to be in the range of $50 million to $53 million, an increase of 54% to 63% compared with 2024," continued Mr. Gudonis.

    Conference Call and Webcast

    Myomo will hold a conference call today at 4:30 p.m. Eastern time to discuss these results and answer questions. Participants are encouraged to pre-register for the call at this link. Callers who pre-register will receive a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time up to and after the start of the call. Those unable to pre-register may participate by dialing 844-707-6932 (U.S.) or 412-317-9250 (International). A webcast of the call will also be available at Myomo's Investor Relations page at http://ir.myomo.com/.

    A replay of the webcast will be available beginning approximately one hour after the completion of the live conference call at http://ir.myomo.com/. A dial-in replay of the call will be available until May 21, 2025 at 877-344-7529 (U.S. toll-free), 855-669-9658 (Canada toll-free) or 412-317-0088 (International), with passcode 6665274.

    Non-GAAP Financial Measures

    Myomo is providing financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. This information includes Adjusted EBITDA. This non-GAAP financial measure is not in accordance with, or an alternative for, GAAP and may be different from similar non-GAAP financial measures used by other companies. Myomo believes the use of this non-GAAP financial measure provides supplementary information for investors to use in evaluating operating performance and in comparing Myomo's financial measures with other companies in its industry, many of which present similar non-GAAP financial measures. Adjusted EBITDA is EBITDA adjusted for stock-based compensation expense and loss on equity investment. This non-GAAP financial measure is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP, and should be viewed in conjunction with GAAP financial measures. Investors are encouraged to review the reconciliation of this non-GAAP measure to its most directly comparable GAAP financial measure. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables included as part of this press release.

    About Myomo

    Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient's own EMG signals through non-invasive sensors on the arm, can restore an individual's ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Burlington, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.

    Forward-Looking Statements

    This press release contains forward-looking statements regarding the Company's future business expectations, including expectations for second quarter and full year 2025 revenue, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.

    These factors include, among other things:

    • our ability to obtain sufficient reimbursement from third-party payers for our products;
    • our ability to scale the business to return to positive cash flow from operations on a quarterly basis by the fourth quarter of 2025;
    • our revenue concentration with Medicare and with a particular insurance payer as a result of focusing our efforts on patients with insurers who have previously reimbursed for the MyoPro;
    • our ability to continue normal operations and patient interactions without supply chain disruption in order to deliver and fit our custom-fabricated devices;
    • our marketing and commercialization efforts;
    • our dependence upon external sources for the financing of our operations, to the extent that we do not achieve or maintain cash flow breakeven;
    • our ability to obtain and maintain our strategic collaborations and to realize the intended results of such collaborations;
    • our ability to effectively execute our business plan and scale up our operations;
    • our ability to remediate the material weakness in our internal control over financial reporting;
    • our expectations as to our product development programs, including improving our existing products and developing new products;
    • our ability to maintain and grow our reputation and to achieve and maintain the market acceptance of our products;
    • our expectations as to our clinical research program and clinical results;
    • our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others;
    • our ability to gain and maintain regulatory approvals;
    • our ability to compete and succeed in a highly competitive and evolving industry; and
    • general market, economic, environmental and social factors that may affect the evaluation, fitting, delivery and sale of our products to patients.

    More information about these and other factors that potentially could affect our financial results is included in Myomo's filings with the Securities and Exchange Commission, including those contained in the risk factors section of the Company's annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material or adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

    (Tables follow)

    MYOMO, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

     

     

     

    For the Three Months Ended

     

     

     

    March 31,

     

     

     

    2025

     

     

    2024

     

    Revenue

     

     

     

     

     

     

    Product revenue

     

    $

    9,831,814

     

     

    $

    3,754,389

     

     

     

     

     

     

     

     

    Cost of revenue

     

     

    3,222,184

     

     

     

    1,455,345

     

    Gross profit

     

     

    6,609,630

     

     

     

    2,299,044

     

    Operating expenses:

     

     

     

     

     

     

    Research and development

     

     

    1,790,024

     

     

     

    956,215

     

    Selling, clinical and marketing

     

     

    4,395,804

     

     

     

    2,361,845

     

    General and administrative

     

     

    3,944,056

     

     

     

    2,869,751

     

     

     

     

    10,129,884

     

     

     

    6,187,811

     

     

     

     

     

     

     

     

    Loss from operations

     

     

    (3,520,254

    )

     

     

    (3,888,767

    )

     

     

     

     

     

     

     

    Other (income) expense, net

     

     

     

     

     

     

    Interest income, net

     

     

    (191,991

    )

     

     

    (135,293

    )

     

     

     

    (191,991

    )

     

     

    (135,293

    )

    Loss before income taxes

     

     

    (3,328,263

    )

     

     

    (3,753,474

    )

    Income tax expense

     

     

    136,795

     

     

     

    82,158

     

    Net loss

     

    $

    (3,465,058

    )

     

    $

    (3,835,632

    )

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Weighted average number of common shares outstanding:

     

     

     

     

     

     

    Basic and diluted

     

     

    41,454,472

     

     

     

    36,752,597

     

    Net loss per share attributable to common stockholders

     

     

     

     

     

     

    Basic and diluted

     

    $

    (0.08

    )

     

    $

    (0.10

    )

    MYOMO, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

     

     

    March 31,

     

     

    December 31,

     

     

     

    2025

     

     

    2024

     

     

     

    (unaudited)

     

     

     

     

    ASSETS

     

     

     

     

     

     

    Current Assets:

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    19,793,799

     

     

    $

    24,372,373

     

    Short-term investments

     

     

    1,730,460

     

     

     

    492,990

     

    Accounts receivable, net

     

     

    4,663,398

     

     

     

    3,825,291

     

    Inventories, net

     

     

    3,368,502

     

     

     

    3,165,965

     

    Prepaid expenses and other current assets

     

     

    1,541,118

     

     

     

    933,377

     

    Total Current Assets

     

     

    31,097,277

     

     

     

    32,789,996

     

    Restricted cash

     

     

    375,000

     

     

     

    375,000

     

    Operating lease assets with right of use

     

     

    7,295,711

     

     

     

    7,584,663

     

    Equipment, net

     

     

    1,842,254

     

     

     

    1,330,008

     

    Other assets

     

     

    257,085

     

     

     

    164,412

     

    Total Assets

     

    $

    40,867,327

     

     

    $

    42,244,079

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

     

     

     

    Current Liabilities:

     

     

     

     

     

     

    Accounts payable and accrued expenses

     

     

    10,448,565

     

     

     

    9,021,817

     

    Current operating lease liability

     

     

    765,616

     

     

     

    748,021

     

    Income taxes payable

     

     

    331,236

     

     

     

    318,885

     

    Deferred revenue

     

     

    129,852

     

     

     

    83,115

     

    Total Current Liabilities

     

     

    11,675,269

     

     

     

    10,171,838

     

    Non-current operating lease liability

     

     

    7,504,994

     

     

     

    7,358,184

     

    Total Liabilities

     

     

    19,180,263

     

     

     

    17,530,022

     

    Commitments and Contingencies

     

     

    —

     

     

     

    —

     

    Stockholders' Equity:

     

     

     

     

     

     

    Preferred stock

     

     

    —

     

     

     

    —

     

    Common stock

     

     

    3,446

     

     

     

    3,439

     

    Additional paid-in capital

     

     

    128,386,223

     

     

     

    127,846,026

     

    Accumulated other comprehensive loss

     

     

    (116,545

    )

     

     

    (14,406

    )

    Accumulated deficit

     

     

    (106,579,596

    )

     

     

    (103,114,538

    )

    Treasury stock, at cost

     

     

    (6,464

    )

     

     

    (6,464

    )

    Total Stockholders' Equity

     

     

    21,687,064

     

     

     

    24,714,057

     

    Total Liabilities and Stockholders' Equity

     

    $

    40,867,327

     

     

    $

    42,244,079

     

    MYOMO, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    For the Three Months Ended March 31,

     

    2025

     

     

    2024

     

    CASH FLOWS FROM OPERATING ACTIVITIES

     

     

     

     

     

     

    Net loss

     

    $

    (3,465,058

    )

     

    $

    (3,835,632

    )

    Adjustments to reconcile net loss to net cash used in operations:

     

     

     

     

     

     

    Depreciation

     

     

    158,442

     

     

     

    29,685

     

    Stock-based compensation

     

     

    540,204

     

     

     

    320,288

     

    Accretion of discount on short-term investments

     

     

    (11,747

    )

     

     

    (49,053

    )

    Bad debt expense

     

     

    51,643

     

     

     

    —

     

    Amortization of right-of-use assets

     

     

    288,951

     

     

     

    58,658

     

    Amortization of deferred offering cost

     

     

    29,039

     

     

     

    —

     

    Other non-cash charges

     

     

    (34,171

    )

     

     

    63,930

     

    Changes in operating assets and liabilities:

     

     

     

     

     

     

    Accounts receivable

     

     

    (637,054

    )

     

     

    718,676

     

    Inventories

     

     

    (550,772

    )

     

     

    (597,087

    )

    Prepaid expenses and other current assets

     

     

    (628,186

    )

     

     

    6,897

     

    Other assets

     

     

    (70,210

    )

     

     

    —

     

    Accounts payable and accrued expenses

     

     

    1,440,877

     

     

     

    87,041

     

    Operating lease liabilities

     

     

    164,405

     

     

     

    (115,191

    )

    Deferred revenue

     

     

    46,738

     

     

     

    (11,181

    )

    Income taxes payable

     

     

    —

     

     

     

    77,405

     

    Net cash used in operating activities

     

     

    (2,676,899

    )

     

     

    (3,245,564

    )

    CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES

     

     

    (1,896,098

    )

     

     

    (3,542,565

    )

    CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES

     

     

    (36,506

    )

     

     

    5,361,909

     

    Effect of foreign exchange rate changes on cash

     

     

    30,929

     

     

     

    (10,360

    )

     

     

     

     

     

     

     

    Net increase in cash, cash equivalents and restricted cash

     

     

    (4,578,574

    )

     

     

    (1,436,580

    )

     

     

     

     

     

     

     

    Cash, cash equivalents and restricted cash, beginning of period

     

     

    24,747,373

     

     

     

    6,871,306

     

     

     

     

     

     

     

     

    Cash, cash equivalents and restricted cash, end of period

     

    $

    20,168,799

     

     

    $

    5,434,726

     

    MYOMO, INC.

    RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA

    (unaudited)

     

     

    For the Three Months

    Ended March 31,

     

     

     

    2025

     

     

    2024

     

    GAAP net loss

     

    $

    (3,465,058

    )

     

    $

    (3,835,632

    )

    Adjustments to reconcile to Adjusted EBITDA:

     

     

     

     

     

     

    Interest income, net

     

     

    (191,991

    )

     

     

    (135,293

    )

    Depreciation expense

     

     

    158,442

     

     

     

    29,685

     

    Stock-based compensation

     

     

    540,204

     

     

     

    320,288

     

    Income tax expense

     

     

    136,795

     

     

     

    82,158

     

    Adjusted EBITDA

     

    $

    (2,821,608

    )

     

    $

    (3,538,794

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250507851091/en/

    Myomo:

    [email protected]



    Alliance Advisors IR:

    Tirth T. Patel

    [email protected]

    212-201-6614

    Get the next $MYO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MYO

    DatePrice TargetRatingAnalyst
    7/31/2024$7.00Buy
    Craig Hallum
    5/20/2024$7.00Buy
    Lake Street
    12/15/2023$6.50Buy
    H.C. Wainwright
    More analyst ratings

    $MYO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Myomo Reports First Quarter 2025 Financial and Operating Results

      Revenue of $9.8 million Record 700 patients added to the pipeline More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2025. Financial and operating highlights for the first quarter of 2025 include the following (all comparisons are with the first quarter of 2024 unless otherwise indicated): Revenue was $9.8 million, up 162%; Revenu

      5/7/25 5:11:00 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo to Host Investor & Analyst Day Event on June 18, 2025

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces the Company will be hosting its first-ever Investor & Analyst Day event on Wednesday, June 18, 2025. The event will take place at Myomo's new corporate headquarters and manufacturing facility in Burlington, Mass., and will offer an in-depth look at the Company's latest innovations, strategic plans and growth initiatives to empower individuals with neuromuscular disorders through cutting-edge wearable medical robotics. Institutional investors, shareholders and analysts are invited to reg

      5/1/25 8:30:00 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo to Report First Quarter 2025 Financial Results on May 7

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2025 on May 7, 2025. The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the cal

      4/30/25 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Myomo Inc.

      SC 13G/A - MYOMO, INC. (0001369290) (Subject)

      10/18/24 2:21:35 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Myomo Inc.

      SC 13G/A - MYOMO, INC. (0001369290) (Subject)

      7/12/24 10:35:49 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Myomo Inc.

      SC 13G/A - MYOMO, INC. (0001369290) (Subject)

      7/11/24 6:02:07 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MYO
    SEC Filings

    See more

    $MYO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $MYO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MYO
    Financials

    Live finance-specific insights

    See more
    • Amendment: Chief Commercial Officer Mitchell Micah sold $247,565 worth of shares (48,000 units at $5.16), decreasing direct ownership by 25% to 140,269 units (SEC Form 4)

      4/A - MYOMO, INC. (0001369290) (Issuer)

      3/21/25 4:15:53 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Director Kirk Thomas F bought $37,000 worth of shares (7,400 units at $5.00), increasing direct ownership by 3% to 255,933 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      3/14/25 9:00:08 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Amendment: Chief Commercial Officer Mitchell Micah sold $247,565 worth of shares (48,000 units at $5.16), decreasing direct ownership by 25% to 140,572 units (SEC Form 4)

      4/A - MYOMO, INC. (0001369290) (Issuer)

      3/14/25 5:45:37 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by Myomo Inc.

      10-Q - MYOMO, INC. (0001369290) (Filer)

      5/7/25 4:15:23 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MYOMO, INC. (0001369290) (Filer)

      5/7/25 4:10:10 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • SEC Form DEFA14A filed by Myomo Inc.

      DEFA14A - MYOMO, INC. (0001369290) (Filer)

      4/25/25 8:35:25 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Craig Hallum initiated coverage on Myomo with a new price target

      Craig Hallum initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

      7/31/24 7:20:07 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Lake Street initiated coverage on Myomo with a new price target

      Lake Street initiated coverage of Myomo with a rating of Buy and set a new price target of $7.00

      5/20/24 9:00:38 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • H.C. Wainwright initiated coverage on Myomo with a new price target

      H.C. Wainwright initiated coverage of Myomo with a rating of Buy and set a new price target of $6.50

      12/15/23 8:26:14 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Director Kirk Thomas F bought $37,000 worth of shares (7,400 units at $5.00), increasing direct ownership by 3% to 255,933 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      3/14/25 9:00:08 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Kirk Thomas F bought $175,000 worth of shares (50,000 units at $3.50), increasing direct ownership by 27% to 236,499 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      5/31/24 5:43:26 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Kirk Thomas F bought $175,000 worth of shares (50,000 units at $3.50), increasing direct ownership by 37% to 186,499 units (SEC Form 4)

      4 - MYOMO, INC. (0001369290) (Issuer)

      3/18/24 7:48:52 AM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo Reports First Quarter 2025 Financial and Operating Results

      Revenue of $9.8 million Record 700 patients added to the pipeline More than 300 Certified Prosthetists Orthotists have completed initial MyoPro® training Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended March 31, 2025. Financial and operating highlights for the first quarter of 2025 include the following (all comparisons are with the first quarter of 2024 unless otherwise indicated): Revenue was $9.8 million, up 162%; Revenu

      5/7/25 5:11:00 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo to Report First Quarter 2025 Financial Results on May 7

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the first quarter ended March 31, 2025 on May 7, 2025. The Company will host a conference call the same day at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, chairman and chief executive officer, and David Henry, chief financial officer. Participants are encouraged to pre-register for the conference call using this link. Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the cal

      4/30/25 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care
    • Myomo's Fourth Quarter Financial Results Feature Record Revenue of $12.1 Million

      Generated first-ever positive quarterly cash flow from operations Received a record 233 MyoPro® authorizations and orders with 657 additions to the pipeline Introduces 2025 revenue guidance of $50 million to $53 million Conference call being held today at 4:30pm Eastern time Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months and year ended December 31, 2024. Financial and operating highlights for the fourth quarter of 2024 include the following (all comparisons are with the fourth quarter of

      3/10/25 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care

    $MYO
    Leadership Updates

    Live Leadership Updates

    See more
    • Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

      Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

      2/3/25 4:00:00 PM ET
      $INGN
      $MDT
      $MYO
      Industrial Specialties
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Myomo Appoints Heather Getz to its Board of Directors

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Heather Getz as a Class II director and chair of its audit committee effective March 26, 2024, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has seven directors. Ms. Getz brings more than 25 years of corporate experience creating long-term value through financial, general management, and healthcare leadership. She has significant expertise in finance, reimbursement, investor relations, compliance, M&A and strategic plannin

      3/28/24 4:05:00 PM ET
      $BFLY
      $MYO
      Medical Electronics
      Health Care
      Industrial Specialties
    • Myomo Appoints Yitzchak Jacobovitz to its Board of Directors

      Myomo, Inc. (NYSE:MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class II director effective January 27, 2023, to serve until the 2025 annual meeting of stockholders. With this appointment, Myomo has six directors. Mr. Jacobovitz, 47, is currently a partner and lead healthcare analyst at AIGH Capital Management and affiliates ("AIGH"), where he has significantly grown AIGH's healthcare footprint since joining in 2014. Prior to AIGH, Mr. Jacobovitz was a managing director at Capstone, a policy research

      1/30/23 4:05:00 PM ET
      $MYO
      Industrial Specialties
      Health Care